Antiviral Drug Susceptibility of Influenza Viruses

The subject of choice for long-term projects is based on their sensitivity to antiviral drug research and development and influenza virus resistance. In the early 1960s, antiviral research was considered a relatively young field, but its first major impact continued to expand and achieved incredible results (Field & De Clercq, 2004). With this project, the general process of antiviral drugs and antiretroviral drugs such as safety and efficacy assessment, protection, use of multiple drug combinations to overcome antiviral drug resistance, and drug resistance I was able to understand better.

Antiviral drugs are very important for the treatment of influenza and pandemic influenza. To date, almost all influenza A viruses prevalent in humans have inhibitory effects against certain classes of antiviral drugs - M2 inhibitors (amantadine and rimantadine). However, the tolerance to the neuraminidase inhibitor oseltamivir is still very low (1-2%). The susceptibility of antiviral drugs is continually monitored through the WHO Global Influenza Surveillance and Response System. The WHO provides technical assistance to help each country formulate national action plans and strengthen health and surveillance systems to prevent and manage antibiotic resistance. We are collaborating with partners to strengthen the evidence base and develop new response to this global threat.

People who have been exposed to infected birds can prophylactically administer anti-influenza antiviral drugs. Antiviral drugs are most commonly used to treat influenza but can also be used to prevent infection by people who have been exposed to influenza virus. When used for the prevention of seasonal influenza, the effective rate of antiviral drugs is 70% to 90%. The US Centers for Disease Control and Prevention issued interim guidelines on follow-up of people infected with Avian A virus A and influenza antiviral chemoprevention to US clinicians and public health professionals.

Antiviral drugs against influenza virus may reduce the effectiveness of LAIV. If you are taking anti-flu medicine, please do not take LAIV within 48 hours after the last dose. If you are taking antiviral drugs within 14 days after inoculation with nasal spray influenza vaccine, you need to receive immunization. However, inactivated influenza vaccine (IIV) can be offered to people taking influenza antiviral drugs. Half of the LAIV (or other vaccine) is a nonstandard dose and should not be counted. If you can not give the second half of the vaccine with the same promise, you will have to provide another full dose of influenza vaccine at another time. Alternatively, you can administer inactivated influenza vaccine at any time after this partial dose. If you want to give LAIV again, you should wait around because it is a live vaccine